Accumulating evidence has proved that SMAD4 is a key downstream effector of transforming growth factor-β (TGF-β) signaling pathway, which is known to reduce breast cancer cell invasion and tumor-induced angiogenesis [41,42]. Here, TGFB1 is linked to breast carcinoma.